Regulating Regenexx: The Role of FDA Oversight in Regenerative Medicine
&srotate=0)
Regulating Regenerative Medicine
Regenerative therapies, such as Platelet-Rich Plasma (PRP) and bone marrow-derived stem cell procedures, offer exciting advancements in modern medical treatments. However, with rapid growth in these therapies, regulatory bodies must work to keep the public informed and ensure safety. The U.S. Food and Drug Administration (FDA) plays a vital role in overseeing these procedures to ensure they are effective and safe for patients.
PRP and Stem Cell Therapies: The Science Behind the Treatment
PRP therapy enhances healing by collecting and concentrating the patient's own platelets, which are then injected into injured tissues or joints. This treatment is widely used in sports medicine and orthopedic clinics. Stem cell therapy, on the other hand, has a broader application due to the ability of stem cells to develop into different cell types, making it a versatile option for various conditions. Bone marrow concentrate therapies, such as those by Regenexx, represent a refined and premier application of these healing cells in orthopedic and musculoskeletal care.
FDA's Regulatory Framework: Balancing Safety and Innovation
The FDA regulates regenerative medicine products using a risk-based framework. This framework classifies human cells, tissues, and cellular/tissue-based products (HCT/Ps) under two key categories in the Public Health Service Act: Section 351 and Section 361.
- Section 351 Products: Products in this category are considered higher-risk, requiring more rigorous oversight. These therapies must undergo extensive clinical trials and obtain pre-market FDA approval before becoming available to patients. Most stem cell therapies fall into this category due to the potential for significant side effects. Companies offering these treatments must submit an Investigational New Drug (IND) application to begin clinical trials and move toward market approval. However, if bone marrow-derived stem cells are harvested, processed, and injected into target musculoskeletal tissues on the same day, as is the case with proprietary Regenexx treatments, the procedure is treated differently under FDA guidelines and may not require classification as a drug.
- Section 361 Products: In contrast, Section 361 products are considered lower-risk and are subject to fewer regulatory requirements. They must meet basic criteria, such as homologous use and minimal manipulation, to avoid the need for pre-market approval. PRP procedures typically fall under Section 361 because they involve minimal processing of the patient’s own blood. In the case of Regenexx's same-day bone marrow concentrate injections, the timeframe for sample collection, processing, and injection plays a key role in determining whether the procedure is classified as a drug under Section 351 or exempt under Section 361.
Regulating PRP: FDA's Approach to Autologous Therapies
Since PRP therapy uses the patient’s own blood (autologous treatment), it is typically regulated under Section 361. The FDA has determined that PRP poses minimal risk and primarily focuses on ensuring that Good Manufacturing Practices (GMP) are followed. This helps prevent contamination and ensures consistency in the product. FDA guidelines clarify the conditions under which PRP therapies can be marketed without needing pre-market approval. Regenexx’s PRP therapy adheres to these guidelines and falls under the same Section 361 classification, ensuring it meets regulatory standards.
Bone Marrow Concentrate: Where Regenexx Fits into FDA Classifications
Bone marrow concentrate treatments, such as those offered by Regenexx, fall into a unique regulatory category because they involve harvesting the regenerative cells from the patient's bone marrow, processing the sample in a laboratory, and reinjecting the resulting serum into the target musculoskeletal tissues—all within the same day, or a 24-hour window. Under FDA guidelines, the same-day processing of bone marrow concentrate exempts it from being classified as a drug, which would otherwise require an IND application under Section 351. This is due to minimal manipulation of the cells and the autologous nature of the treatment, keeping it within the lower-risk category of Section 361.
Looking Ahead: The FDA’s Continued Role in Regenerative Medicine
The FDA's approach to regulating PRP and stem cell therapies underscores its commitment to balancing patient safety with medical innovation. As regenerative medicine continues to evolve, the FDA's regulatory framework will adapt to meet new challenges while ensuring that these therapies are both safe and effective.
For those interested in exploring regenerative treatments, Dr. Matthew Kohler at Ospina Medical is a trusted Regenexx provider who has undergone specialized training and abides by all FDA regulations. If you're curious about whether Regenexx's PRP or bone marrow concentrate therapies are right for you, book a consultation with our team today to start your personalized pain management journey!
Written By: Anwar Alhariri
Edited By: Camden Rowe
Medically Reviewed By: Matthew Kohler, MD